Table II.

In vivo antitumor effects of survivin siRNA nanoliposome on Balb/c nude mice bearing MHCC-97H tumor cells.

	NC-IV		DOX		SU-IV		SU-IT
Day	RTV	BW/g	RTV	BW/g	RTV	BW/g	RTV	BW/g
Day 0	/	20.50±1.26	/	21.00±0.82	/	21.33±0.62	/	21.33±0.62
Day 3	1.85±0.39	22.00±0.41	1.28±0.29	22.17±0.80	1.33±0.59	22.17±0.37	1.31±0.20	22.50±0.82
Day 6	2.88±0.72	22.75±0.56	2.08±1.03	23.08±0.89	1.98±1.02	23.17±0.37	2.12±0.69	23.00±0.65
Day 10	5.07±1.33	23.42±0.84	3.67±2.03	23.58±1.20	2.99±1.63a	24.08±0.53	2.69±0.93b	23.92±1.27
Day 13	10.38±2.97	23.42±1.06	6.40±3.60	24.00±1.35	5.39±3.47a	24.08±0.53	5.74±1.70b	24.08±1.20
Day 17	14.71±2.76	23.50±1.00	8.85±4.58a	23.58±1.20	8.77±6.24	24.50±0.58	7.90±2.25b	24.25±1.18
Day 20	29.86±8.76	24.17±0.69	16.28±8.98a	23.50±1.12	13.72±9.82a	24.75±0.25	14.47±4.62b	24.92±1.20
Day 24	39.54±11.55	25.25±0.75	23.34±12.45a	24.17±0.85	19.62±12.47a	26.08±0.34	19.64±3.61b	26.00±0.91
Day 27	61.77±17.38	25.58±0.89	32.09±21.34a	3.58±0.73	24.62±15.27b	26.50±0.65	31.68±10.34b	26.08±0.79
Day 31	76.94±23.28	25.17±1.03	40.86±25.85a	24.00±1.29	34.53±21.35b	26.25±0.48	39.75±11.75b	26.17±0.85

^aP<0.05

^bP<0.01 vs. the NC-IV group. RTV, relative tumor volume; BW/g, body weight/gram; NC-IV, negative control small interfering RNA administered intravenously; DOX, intraperiotoneal injection of doxorubicin hydrochloride; SU-IV, intravenous injection of survivin small interfering RNA nanoliposome; SU-IT, intratumoral injection of survivin small interfering RNA nanoliposome.